Treating COVID-19 in the Pediatric Population
Pharmacy Times
JANUARY 5, 2023
An overview of current theses and research surrounding the pathogenesis, presentation, and treatment of COVID-19 in children.
research research-overview 
Artificial Intelligence & Antimicrobial Stewardship: An Interview With ChatGPT
IDStewardship
JUNE 5, 2023
This can help researchers identify novel targets, repurpose existing drugs, and design new molecules with enhanced antimicrobial activity, potentially overcoming resistance mechanisms. Is it appropriate for medical professionals to use artificial intelligence software in medical research or publishing?
Vaccines 
234
234 Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Five Ways Preceptors May Integrate Generative Artificial Intelligence Programs Into Pharmacy Education Learning Experiences
IDStewardship
DECEMBER 12, 2023
In terms of pharmacy education research on the topic of AI, there is not a lot out there. The cross roads of GenAI and pharmacy education may additionally be ripe for pharmacist researchers seeking a niche field. Two of their quotes resinated with me. .” Potential GenAI applications are vast and rapidly emerging.
Communication 274
274 
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 overview KFA-115 is under development for the treatment of hematological tumor and melanoma, renal cell carcinoma, ovarian cancer, nasopharyngeal cancer, thymic carcinoma, anal cancer, malignant mesothelioma, esophageal cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer.
Comprehensive review finds limited evidence for antidepressants in chronic pain
Hospital Pharmacy Europe
FEBRUARY 8, 2023
The effectiveness of an antidepressant for the management of chronic pain appears to be limited according to an overview of systematic reviews In an overview of systematic reviews a team from Australia and the UK found that there is limited evidence to support the use of an antidepressant for a wide range of chronic pain conditions.
Hospitals 52
52 Hospitals 52
52 
‘Innovation-first’ mindset vital for advanced therapies sector future
European Pharmaceutical Review
DECEMBER 7, 2023
According to the ATTC Network, experts at the event suggested investment into reinforcing the UK’s already highly skilled research workforce and expediting clinical trial approvals. These actions were outlined as key priorities in the report, to facilitate rapid action and an ‘innovation-first’ mindset.
90 
ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
ZNA-1041 overview ZNA-1041 is under development for the treatment of HER2-positive advanced solid tumor, advanced breast cancer, gastric cancer and breast cancer with brain metastases. Hoffmann-La Roche overview F. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases.
Immunization 52
52 
Who’s posting what? Big Data related social media posts increased by 11% in the pharma industry in Q1 2023
Pharmaceutical Technology
JUNE 6, 2023
GlobalData’s Big Data in Pharmaceuticals – Thematic Research report offers an overview of the current landscape, trends, and leading companies, and highlights the opportunities for the use of big data analytics in the future. Buy the report here.
52 
BBT-401 by Bridge Biotherapeutics for Ulcerative Colitis: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
BBT-401 overview BBT-401 is under development for the treatment of multiple sclerosis, ulcerative colitis and age related macular degeneration. Bridge Biotherapeutics also carries out the research and development and innovation of new drugs. It is administered through oral and rectal route.
52 
Who’s saying what? Big Data mentions in company filings of pharmaceutical industry decreased by 13% in Q1 2023
Pharmaceutical Technology
MAY 29, 2023
GlobalData’s Big Data in Pharmaceuticals – Thematic Research report offers an overview of the current landscape, trends, and leading companies, and highlights the opportunities for the use of big data analytics in the future. Buy the report here. Starting at 100 in 2020, an index over 100 is more positive.
ACD-440 by AlzeCure Pharma for Neuropathic Pain (Neuralgia): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
ACD-440 overview ACD-440 is under development for the treatment of neuropathic pain including painful peripheral polyneuropathy, peripheral mononeuropathy, postherpetic neuralgia (PHN), chemotherapy induced neuropathic pain, nerve injury pain, chronic postoperative neuropathic pain and peripheral neuropathic pain.
Chemotherapy 40
40 
NuGel by Shaperon for Sepsis: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
NuGel overview NuGel (sodium taurodeoxycholic acid) is under development for the treatment of atopic dermatitis and sepsis. Shaperon overview Shaperon is a biopharmaceutical development company that is engaged in research and development of pneumonia therapy and alzheimer’s disease therapy. It acts by targeting the GPCR19.
40 
NuGel by Shaperon for Sepsis: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
NuGel overview NuGel (sodium taurodeoxycholic acid) is under development for the treatment of atopic dermatitis and sepsis. Shaperon overview Shaperon is a biopharmaceutical development company that is engaged in research and development of pneumonia therapy and alzheimer’s disease therapy. It acts by targeting the GPCR19.
40 
What Are the Most Common Symptoms of Long COVID?
The People's Pharmacy
JUNE 8, 2023
Unfortunately, researchers have had trouble studying it because they needed a uniform definition. Previous Research on Symptoms of Long COVID: This report in JAMA is not the only in-depth exploration of the symptoms of long COVID. They published their extensive overview in Nature Reviews Microbiology (Jan. What About Treatment?
Hospitals 62
62 Hospitals 62
62 
KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 overview KFA-115 is under development for the treatment of hematological tumor and melanoma, renal cell carcinoma, ovarian cancer, nasopharyngeal cancer, thymic carcinoma, anal cancer, malignant mesothelioma, esophageal cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer.
ABN-401 by Abion for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 20, 2023
ABN-401 overview ABN-401 is under development for the treatment of gastric cancer, metastatic solid tumors such as non-small cell lung cancer, melanoma, breast cancer, sarcoma, carcinoma and prostate cancer. Abion overview Abion is a biopharmaceutical company. It acts by targeting hepatocyte growth factor receptor (HGFR) or c met.
40 
Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
Lopinavir + ritonavir) overview Lopinavir in combination with ritonavir (R-131) is under development for the treatment of genital warts (condylomata acuminata) and cervical intraepithelial neoplasia. Douglas collaborates with scientific researchers and external medical experts to advance clinical research.
40 
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
Lopinavir + ritonavir) overview Lopinavir in combination with ritonavir (R-131) is under development for the treatment of genital warts (condylomata acuminata) and cervical intraepithelial neoplasia. Douglas collaborates with scientific researchers and external medical experts to advance clinical research.
40 
Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy
Roots Analysis
FEBRUARY 27, 2024
Why is CRISPR gaining so much traction: Over the years, more than 10,000 patents related to the CRISPR technology have been filed/granted to various industry players and academic institutions, indicative of the ongoing pace of R&D in this field of research.
40 
Who’s posting what? Regenerative Medicine related social media posts increased by 11% in the pharma industry in Q1 2023
Pharmaceutical Technology
JUNE 6, 2023
GlobalData’s Regenerative Medicine in Medical thematic intelligence report provides an overview of the current landscape, including healthcare, technology, regulatory, macroeconomic trends, and key players. For further understanding of GlobalData's Regenerative Medicine in Medical - Thematic Research buy the report here.
40 
Applied Virtual Reality in Healthcare: A comprehensive book on medical XR
pharmaphorum
JANUARY 27, 2022
Our book Applied Virtual Reality in Healthcare provides an overview of innovative approaches, best practices, and coherent solutions to common concerns. “Our Our book Applied Virtual Reality in Healthcare provides an overview of innovative approaches, best practices, and coherent solutions to common concerns. About the interviewee.
Chemotherapy 142
142 Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide overview Rezvilutamide is an antineoplastic agent. Jiangsu Hengrui Medicine overview Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products.
40 Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide overview Rezvilutamide is an antineoplastic agent. Jiangsu Hengrui Medicine overview Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products.
40 ATRN-119 by Aprea Therapeutics for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
ATRN-119 overview ATRN-119 is under development for the treatment of advanced solid tumors including ovarian cancer, endometrial cancer, cervical cancer, colon cancer, breast cancer and prostate cancer. It also has pre-clinical research and development to extend its product development.
40 
Analytica 2024 in overview
European Pharmaceutical Review
MARCH 5, 2024
Given the rising data flood, especially in life sciences, digital solutions for research data management are urgently needed, as highlighted in various lecture series of the analytica conference. analytica 2024 provides a comprehensive overview of innovative analytics and molecular – as well as microbiological – testing methods.
Labelling 93
93 
Calls for urgent action to tackle burnout across UK pharmacy sector
Hospital Pharmacy Europe
OCTOBER 9, 2023
A lack of funding to support pharmacists and their teams is impacting staff wellbeing and more research is required to understand the ‘most effective measures’ to address workforce issues, the report adds. The report said: ‘Indeed, it is concerning that there is a positive correlation of data between NHS staff survey wellbeing and mortality.
Hospitals 52
52 Hospitals 52
52 
PM Society Training: Essentials of Pharmaceutical Marketing
pharmaphorum
JUNE 2, 2021
Overview of pharmaceutical marketing. Developing true customer insights through effective market research. Understanding of key market research principles and practices. Who will benefit? New and aspiring marketers and those wanting to refresh their marketing thinking and be fitter to handle today’s healthcare environment.
52 
Pralsetinib by F. Hoffmann-La Roche for Pancreatic Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Pralsetinib overview Pralsetinib (Gavreto) is an anticancer agent. Hoffmann-La Roche overview F. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists.
Immunization 40
40 
Cell Therapy and Gene Therapy Contract Research Organizations: The Next Growth Opportunity
Roots Analysis
AUGUST 29, 2023
Overview of Cell and Gene Therapies Cell and gene therapy candidates have been demonstrated to have the potential to treat rare and complex diseases, including indications, for which no effective treatment is currently available. What are the Benefits of Contract Research Organizations?
40 
Comparison Of Rebyota Versus Vowst: A Study Table To Help You Compare Fecal Microbiota Therapies
IDStewardship
APRIL 14, 2024
Gut dysbiosis has been the subject of several clinical research studies aiming to better understand its role in rCDI and to ultimately apply that understanding towards the development of preventative treatments. This disruption, or dysbiosis, is a key contributor to gut vulnerability in recurrent CDI (rCDI). Am J Gastroenterol. Gut Microbes.
FDA 324
324 
Pimitespib by Otsuka Pharmaceutical for Metastatic Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
Pimitespib overview Pimitespib (Jeselhy) belongs to a class of antineoplastic drugs. The company operates branch offices, research facilities and factories in Japan. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is a HSP90 inhibitor.
Chemotherapy 40
40 Chemotherapy 40
40 
Pimitespib by Otsuka Pharmaceutical for Metastatic Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
Pimitespib overview Pimitespib (Jeselhy) belongs to a class of antineoplastic drugs. The company operates branch offices, research facilities and factories in Japan. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is a HSP90 inhibitor.
Chemotherapy 40
40 Chemotherapy 40
40 
Delivery systems for biologics
European Pharmaceutical Review
MARCH 4, 2024
Their small size also allows them to cross the blood-brain barrier, which is a vibrant field of research, especially in diseases of the central nervous system (CNS). However, the latest scientific research suggests that we are entering a new era of innovation in this field. Center for Biologics Evaluation and Research.
FDA 94
94 
Sym-021 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
Les Laboratoires Servier overview Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Immunization 40
40 Immunization 40
40 
Setanaxib by Calliditas Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
Setanaxib overview setanaxib (GKT-831; GKT-137831) is under development for the treatment of alport syndrome, kidney disease (nephropathy), primary biliary cholangitis (primary biliary cirrhosis), recurrent head and neck cancer squamous cell carcinoma, idiopathic pulmonary fibrosis. It markets products under the brand TARPEYO.
40 
EU regulators issue guidance on decentralised trials
pharmaphorum
DECEMBER 19, 2022
The recommendations are part of the ACT EU initiative between the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) group – launched earlier this year – intended to further develop the EU’s role as a centre for clinical research. ” Image by OpenClipart-Vectors from Pixabay .
Why R&D innovation holds the key to greater patient impact
European Pharmaceutical Review
MAY 2, 2023
the average duration to develop a new medicine is still around 10-15 years We know that the research and development (R&D) process behind developing new medicines is increasingly complex. Our instinct should be to continually expand clinical research into new partnerships, platforms and modalities wherever possible.
Compounding 104
104 
Edoxaban tosylate by Daiichi Sankyo for Atrial Fibrillation: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 14, 2023
Edoxaban tosylate overview Edoxaban tosylate (Lixiana, Savaysa, Roteas ) is an oral anticoagulant that directly inhibits factor Xa, an important factor in the coagulation process. Daiichi Sankyo overview Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products.
Immunization 40
40 
At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector
Roots Analysis
JANUARY 16, 2023
At-home Self-testing Kits – Market Overview. During our research, we found out that most of the at-home self-testing kits are developed in the form of strips; these strips are primarily used for monitoring diabetes and are approved by various regulatory authorities, such as the USFDA, ISO and IVD.
52 
Orvacabtagene autoleucel by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
Orvacabtagene autoleucel overview Orvacabtagene autoleucel (ET-140) is under development for the treatment of relapsed and refractory multiple myeloma. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need.
Hospitals 40
40 Hospitals 40
40 
GRANITE-001 by Gritstone Bio for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
GRANITE-001 overview GRANITE-001 (Zvexneo) is under development for the treatment of pancreatic ductal adenocarcinoma, microsatellite stable colorectal cancer, metastatic non-small cell lung cancer, gastroesophageal adenocarcinoma, bladder cancer such as metastatic urothelial cancer. It was also under development for colon cancer.
Vaccines 40
40 Vaccines 40
40 
IP Intelligence
Fuld
DECEMBER 14, 2022
Tackle competition and stay ahead in the race for innovation with Fuld’s comprehensive intellectual property research services, covering all sectors of life sciences and engineering. Compare and evaluate the current position of an organization relative to its competitors concerning patented technology, research, innovation, and business.
52 
Let's personalize your content